Financial Advocates Investment Management Boosts Stock Position in Kenvue Inc. (NYSE:KVUE)

Financial Advocates Investment Management boosted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 208.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 38,113 shares of the company's stock after acquiring an additional 25,752 shares during the period. Financial Advocates Investment Management's holdings in Kenvue were worth $814,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. AMF Tjanstepension AB lifted its position in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company's stock worth $2,787,000 after acquiring an additional 78,540 shares in the last quarter. Mather Group LLC. lifted its holdings in Kenvue by 62.0% during the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company's stock worth $159,000 after purchasing an additional 2,625 shares in the last quarter. Atomi Financial Group Inc. bought a new position in Kenvue in the 3rd quarter worth about $212,000. Perpetual Ltd boosted its stake in Kenvue by 2.6% in the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company's stock worth $587,000 after purchasing an additional 652 shares during the period. Finally, Juncture Wealth Strategies LLC purchased a new position in Kenvue during the 3rd quarter valued at about $241,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of Kenvue stock traded up $0.35 during trading on Tuesday, hitting $20.93. 10,921,780 shares of the stock traded hands, compared to its average volume of 12,761,109. The firm's fifty day moving average is $21.46 and its 200-day moving average is $22.02. The stock has a market cap of $40.13 billion, a price-to-earnings ratio of 39.49, a PEG ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts expect that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.92%. The ex-dividend date is Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on KVUE shares. Canaccord Genuity Group lowered their price target on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upgraded shares of Kenvue from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $21.00 to $26.00 in a research report on Monday, January 6th. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday. Finally, Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Kenvue presently has an average rating of "Hold" and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.